13/01/2026
𝐅𝐃𝐀 𝐒𝐓𝐀𝐓𝐄𝐌𝐄𝐍𝐓 𝐎𝐍 𝐓𝐇𝐄 𝐕𝐎𝐋𝐔𝐍𝐓𝐀𝐑𝐘 𝐑𝐄𝐂𝐀𝐋𝐋 𝐎𝐅 𝐒𝐄𝐋𝐄𝐂𝐓 𝐈𝐍𝐅𝐀𝐍𝐓 𝐅𝐎𝐑𝐌𝐔𝐋𝐀 𝐏𝐑𝐎𝐃𝐔𝐂𝐓𝐒
The Food and Drug Administration (FDA) informs the public that it is actively overseeing and validating the voluntary recall initiated by Nestlé Philippines involving specific batches of NAN OPTIPRO and NANKID OPTIPRO infant formula products as a precautionary measure following the identification of a potential safety and quality concern.
The voluntary recall follows a reported incident involving a raw material from the manufacturer’s supplier. At present, there are no established food safety or regulatory limits on the raw material identified. The FDA is conducting an ongoing investigation to determine the scope of the issue and to assess any potential safety implications.
In close coordination with the manufacturer, the FDA is verifying the specific affected batches, ensuring the prompt and complete removal of recalled products from physical and online retail outlets, and conducting distribution and communication checks to confirm that recall measures are effectively implemented across the supply chain.
At this time, the FDA has not received any reports of illness or adverse events associated with the recalled products. While no adverse events have been reported, the FDA fully supports this precautionary action to protect public health, especially infants and young children.
The FDA advises consumers to carefully check product batch numbers, immediately discontinue use of any affected products, and strictly follow the recall instructions issued by the manufacturer. An official FDA Advisory for the guidance of the general public will be issued to provide further information and updates.
The FDA will continue to carry out post-market surveillance, inspections, and product assessments to ensure that all regulated products in the market meet established safety and quality requirements. Any significant findings will be promptly disclosed in the interest of transparency and consumer protection.
The FDA remains steadfast in fulfilling its mandate to protect public health and to ensure that all regulated health products available to consumers are safe, of good quality, and compliant with applicable laws and regulations.
𝐅𝐃𝐀 𝐒𝐓𝐀𝐓𝐄𝐌𝐄𝐍𝐓 𝐎𝐍 𝐓𝐇𝐄 𝐕𝐎𝐋𝐔𝐍𝐓𝐀𝐑𝐘 𝐑𝐄𝐂𝐀𝐋𝐋 𝐎𝐅 𝐒𝐄𝐋𝐄𝐂𝐓 𝐈𝐍𝐅𝐀𝐍𝐓 𝐅𝐎𝐑𝐌𝐔𝐋𝐀 𝐏𝐑𝐎𝐃𝐔𝐂𝐓𝐒
The Food and Drug Administration (FDA) informs the public that it is actively overseeing and validating the voluntary recall initiated by Nestlé Philippines involving specific batches of NAN OPTIPRO and NANKID OPTIPRO infant formula products as a precautionary measure following the identification of a potential safety and quality concern.
The voluntary recall follows a reported incident involving a raw material from the manufacturer’s supplier. At present, there are no established food safety or regulatory limits on the raw material identified. The FDA is conducting an ongoing investigation to determine the scope of the issue and to assess any potential safety implications.
In close coordination with the manufacturer, the FDA is verifying the specific affected batches, ensuring the prompt and complete removal of recalled products from physical and online retail outlets, and conducting distribution and communication checks to confirm that recall measures are effectively implemented across the supply chain.
At this time, the FDA has not received any reports of illness or adverse events associated with the recalled products. While no adverse events have been reported, the FDA fully supports this precautionary action to protect public health, especially infants and young children.
The FDA advises consumers to carefully check product batch numbers, immediately discontinue use of any affected products, and strictly follow the recall instructions issued by the manufacturer. An official FDA Advisory for the guidance of the general public will be issued to provide further information and updates.
The FDA will continue to carry out post-market surveillance, inspections, and product assessments to ensure that all regulated products in the market meet established safety and quality requirements. Any significant findings will be promptly disclosed in the interest of transparency and consumer protection.
The FDA remains steadfast in fulfilling its mandate to protect public health and to ensure that all regulated health products available to consumers are safe, of good quality, and compliant with applicable laws and regulations.
